Affimed Framtida tillväxt
Future kriterier kontrolleras 0/6
Vi har för närvarande inte tillräcklig analytikertäckning för att förutsäga tillväxt och intäkter för Affimed.
Viktig information
n/a
Tillväxttakt i vinsten
n/a
Tillväxttakt för EPS
| Biotechs vinsttillväxt | 23.4% |
| Intäkternas tillväxttakt | n/a |
| Framtida avkastning på eget kapital | n/a |
| Bevakning av analytiker | None |
| Senast uppdaterad | n/a |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Ny analys • Apr 16
ASH 2024 Updates Will Validate Clinical Proof Of Concept
Positive clinical results and safety profile of NK cell engagers boost potential revenue and adoption, enhancing net margins and efficacy.Seeking Alpha • Sep 04
Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive Catalysts
Summary On 06/11/24, I published an article on Affimed focused on my belief the company’s upcoming acimtamig update would be positive. It was, and Affimed’s stock popped the next day. The stock has since dropped to below $4/s based, in my opinion, on investor's perceptions that a dilutive capital raise is coming soon. AFMD’s 2Q ’24 Earnings Call is scheduled for tomorrow, 09/05/24. And we are due for an acimtamig and AFM24 3Q ’24 update before the end of the month. Abstracts for ESMO’24 are posted on 09/06/24 and the WCLC starts 09/07/24…will we get the AFM24 update before acimtamig's? While AFMD's assets have shown promise, a potential investment carries high risk and may not be suitable for most investors. Read the full article on Seeking AlphaSeeking Alpha • Jun 11
Affimed: AFM24's Update Was Good, Acimtamig's Should Be Better
Summary Affimed's 06/01/24 update on AFM24 means the company has a second viable commercial asset. This is why the stock popped after ASCO. Acimtamig's update is due before the end of this month. If it is positive, the stock should run again for a possible 3-5x. Although the company will likely raise capital after the announcement, I am comfortable owning shares into the action and I am a fan now for the longer term. The stock is currently trading below a $100M valuation, which makes it more of a high risk/high reward play. And as such, is not suitable for all investors. Read the full article on Seeking AlphaAnalysartikel • Aug 15
The Affimed N.V. (NASDAQ:AFMD) Analysts Have Been Trimming Their Sales Forecasts
One thing we could say about the analysts on Affimed N.V. ( NASDAQ:AFMD ) - they aren't optimistic, having just made a...Seeking Alpha • Oct 10
Affimed downgraded to hold at Stifel as pipeline lacks development clarity
Stifel has downgraded Affimed N.V. (NASDAQ:AFMD) to hold from buy as the firm no longer believes that three upcoming data updates will be positive for the biotech. Stifel also cut its price target for the biotech to $2 from $9 (5% upside based on Friday's close). Analyst Bradley Canino sees upcoming setbacks for AFM13-NK, AFM13 and AFM24, for, respectively, Hodgkin lymphoma, peripheral T-cell lymphoma (PTCL), and solid tumors. The first two candidates are in phase 2, while AFM24 is in phase 1. While company management will meet with the US FDA by the end of the year, "we now anticipate a requirement for additional preclinical work and a re-run of the dose escalation that could lead the the pivotal trial to be delayed ~2 years based on the precedent of Takeda’s TAK-007," he wrote of AFM13-NK. A readout of AFM13 for PTCL in Q4 "feels like a coin flip," he added. "We have low confidence in the 3 monotherapy cohorts [of AFM24], which are furthest advanced, given there were no dose-escalation responses," Canino wrote. Seeking Alpha's Quant Rating views Affimed (AFMD) as a strong sell.Analysartikel • Sep 17
Health Check: How Prudently Does Affimed (NASDAQ:AFMD) Use Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Aug 10
Affimed Q2 2022 Earnings Preview
Affimed (NASDAQ:AFMD) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.18 (-12.5% Y/Y) and the consensus Revenue Estimate is $8.03M (-17.3% Y/Y). Over the last 3 months, EPS estimates have seen 6 upward revisions and 0 downward. Revenue estimates have seen 1 upward revision and 5 downward.Seeking Alpha • Jun 29
Affimed: Preparing For Key Inflection Points
Affimed has generated an impressive pipeline of innate cell engagers programs created using their three-pronged development strategy. These programs target high unmet needs and large market opportunities. Affimed recently finalized a $103.5M public offering, which will help fund the company’s wholly-owned programs to hit key catalysts over the remainder of 2022 and into 2023. The company has planned updates on all three of their wholly-owned programs for the second half of this year. The company is on track for registration-directed studies. I am looking to make one or more discretionary additions in the near term to take advantage of the present share price and will return to a DCA strategy. Despite my bullish outlook, I have put AFMD in the Compounding Healthcare speculative "Bio Boom" Portfolio with a conviction grade of 3 out of 5. Over the past few years, Affimed (AFMD) has constructed a distinguished pipeline of innate cell engagers and has verified their three-pronged development strategy to move the company closer to the next stage of growth. In recent times, Affimed has expanded its R&D prowess and revealed significant proof-of-concept data in heavily pretreated patients with a combination of an innate engager and allogeneic natural killer cells. Moreover, Affimed recently finalized a $103.5M public offering, which will help fund the company's wholly-owned programs to hit key catalysts over the remainder of 2022 and into 2023. Sadly, none of this progress has been able to fend off the selling pressure that has crushed small-cap biotechs over the past year and AFMD is now trading just above its 52-week lows. I believe this is an opportunity to add to my AFMD position ahead of some key inflection points that could spark a potential turnaround in the share price. I intend to provide a brief background on the company and will discuss some upcoming catalysts that could trigger a potential turnaround. In addition, I go over some downside risks that investors should be aware of. Finally, I take a look at the charts to identify some key levels and highlight my strategy for adding to my AFMD position. Background on Affimed Affimed is a biotechnology company that utilizes their "fit-for-purpose" Rock platform to develop "innate cell engagers" or "ICE Molecules". The platform creates multi-specific antibodies that will unlock the body's immune cells to attach to their target that is specific to an indication. Affimed's ICE Molecules link to natural killer "NK" cells and macrophages by the CD16A-binding area, while concurrently binding to the target cancer cells. This connection will allow the innate immune system to engage the cancer cells and will trigger the release of perforins to create holes in the cancer cell's membrane to allow granzymes to initiate apoptosis of the cancer cell. ICE Molecule ( Affimed) Rock Platform Overview (Affimed) It is important to note that the company's ICE Molecules are taking the innate immune system that had essentially missed cancer in the first place and has now allowed it to attack the cancer cells. Moreover, Affimed's ICE molecules won't require harvesting the patient's NK or T-Cells, which gives it a significant advantage over most cell therapies. Affimed's pipeline is filled with ICE Molecule programs in an assortment of indications both as a monotherapy and combination therapies. Affimed Method ( Affimed) The company's lead candidate, AFM13, is being tried as a monotherapy, as well as in adaptive NK cells combo, and in combination with an anti-PD-1 in CD30+ lymphomas. To date, AFM13 has generated impressive data both as a monotherapy and in combination. AFM13 Key Data (Affimed) Extraordinarily, the NK cell combination (AFM13-104) showed inspiring results in 40 heavily pre-treated patients that had a median of six prior lines of therapy. 13 of these patients in the highest dose responded to the treatment with 5 of them undergoing a complete response. Moreover, one of these patients had previously failed CD30 CAR-T therapy. AFM13+NK Cell Combo Complete Response (Affimed) Currently, Affimed has completed enrollment in AFM13's registration-directed study in peripheral T-cell lymphoma. AFM13 has been a proof-of-concept product candidate for Affimed and has the potential to validate the remainder of the company's pipeline programs both as monotherapies and in combination therapies. Affimed Pipeline (Affimed) The company's AFM24 is taking aim at EGFR+ solid tumors, which over 400K patients in the U.S. and 1.5M patients around the world. AFM28 is targeting CD123 in AML which is ready for an IND in the first half of this year. AFM28 is the company CD123 targeting innate cell engager is preparing for IND for acute myeloid leukemia. AFM28 encourages lysis of CD123-positive leukemic blasts in AML patients, either pre-complexed or co-administered with cryopreserved NK cells. In addition to the company's wholly-owned assets, Affimed has partnered programs ROIVANT and Roche's (OTCQX:RHHBY) Genentech. These programs have already provided notable milestone payments and the company still has billions in potential milestones outstanding. Upcoming Inflection Points The company's platform, pipeline, and partnerships should produce several potent catalysts over the coming quarters that should improve the company's outlook and potentially fuel a turnaround in the share price. Affimed Upcoming Inflection Points (Affimed) My focus will primarily be on AFM13, which has completed enrollment for the monotherapy REDIRECT study for relapsed/refractory PTCL. Affimed anticipates topline data from this study in Q4 of this year. So far, the AFM13+NK cells combo has displayed a robust increase in complete responses following two cycles of the recommended Phase II dose. Affimed is moving forward and expects to update investors on its development later this year and potentially present data at a medical conference in the second half of this year. Affimed continues to enroll patients in all three AFM24 clinical trials and is planning to present data in the second half of this year. This should reveal the efficacy of the company's three-pronged strategy. The company recently presented data at EHA that showed AFM28 produced potent anti-tumor activity with "no evidence of off-target cytotoxicity." AFM28 is on track for an IND this month for relapsed and refractory AML. Affimed anticipates starting the Phase I clinical trial in the second half of this year. Affimed is also working with their partners to safeguard access to an off-the-shelf cryo-preserved natural killer cell to use in the development of the company's ICE therapies. Affimed expects to update on their NK cell development strategy in the second half of 2022. Affimed is also working with their partnered programs including their Genentech programs. Affimed has been working on several preclinical programs and has handed them over to Genentech for further preclinical development. Affimed's partnership with Roivant is still pushing AFM32 forward and is in IND-enabling studies. Affimed is eligible for additional milestones in the near term. Turnaround Potential Affimed made significant progress in the first half of 2022 with AFM13, AFM24, and AFM28, all of them showing potential to address major medical needs using the company's three-pronged strategy. The planned updates on all three programs for the second half of this year will keep the company on track to be among the first companies to bring innate cell engagers to registration-directed studies and potentially to the market. But most importantly, Affimed extended the company's cash runway to mid-2024, which allows the company to run past these key inflection points for all their innate cell engagers. Affimed Overview (Affimed ) So, not only does the company have several scheduled for the second half of this year, but they also have adequate cash position to get them through the docket of events. As a result, I suspect these updates will have a durable impact on the share price. Whereas underfunded biotech tickers typically experience a selloff in the subsequent weeks as investors fear a follow-up secondary offering. What is more, Affimed has the potential to collect upsized milestone payments from their partners that could extend that cash runway projection beyond mid-2024. It is possible that we are looking at a biotech that is approaching registration trials with a healthy cash position and has the potential to collect additional milestone payments to add to the coffers. To me, these seem like the conditions needed to entice the market to permit a turnaround in the share price. Downside Risks to Consider Affimed investors need to consider a few looming downside risks when managing their position. First is cash... which is not an immediate threat at the moment. However, Affimed might have to pull the trigger on an offering in order to fund their pipeline and prepare for commercialization. Therefore, investors need to accept there is a strong risk the company will have to perform some form of dilutive funding, which could have a negative impact on the share price. Another risk comes from a potential regulatory failure or weak clinical data. The company is fixated on their Rock Platform and their ICE molecules, so a miss or setback in any one of their programs could cast doubt on all their pipeline programs. Last but not least is competition from other cell therapy companies. At the moment, Affimed has a long list of competitors who are using NK cells and T cells to take on various cancers. Even if Affimed is able to produce best-in-class results in the clinic, the company is going to have to battle in the market to establish a beachhead while several other cell therapy products attempt to do the same. This could make the first few quarters of commercialization a little rocky, which would most likely hurt the share price until the company can prove their products can compete in the market. As a result, I have put AFMD in the Compounding Healthcare speculative "Bio Boom" Portfolio with a conviction grade of 3 out of 5. Charting Out the Strategy In my previous article, I discussed how was going to "take my AFMD position out of mothball and apply some profits in the coming months while it is still trading under $5.00 per share." At that time, I was looking to employ a DCA approach by making additions every couple of weeks until the charts show signs of a potential reversal as long as the share price was below $4.50 per share. I am still going to stick to that strategy, but I am also looking to make one or more discretionary additions in the near term to take advantage of the present share price.Analysartikel • Jun 14
Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Seeking Alpha • Apr 09
Affimed Stock: 3 Points For The Bulls
Affimed experienced a four-month-long sell-off but has caught a bid following their full-year 2021 financial results, where they laid out a transformative 2022. Affimed expects to have three innate engagers in the clinic by the end of this year, which should deliver steady data flow over the next several years. I believe AFMD shareholders should focus on three bullish points that will set up a decade-long chain of dominoes that will lead to success. 2022 could trigger that first domino.Analysartikel • Apr 05
Affimed N.V. (NASDAQ:AFMD) Analysts Just Cut Their EPS Forecasts Substantially
The latest analyst coverage could presage a bad day for Affimed N.V. ( NASDAQ:AFMD ), with the analysts making...Analysartikel • Dec 14
Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Oct 12
Affimed: Preparing For A Bullish 2022
Affimed reported mixed Q2 earnings that revealed more milestone payments from their partnerships. In addition, Affimed reported a healthy cash position that is expected to last into 2H of 2022. Affimed continues to move their wholly-owned and partnered pipeline programs. However, 2022 has several catalysts on the docket that could improve the company’s outlook. Despite the progress, the share price has remained under pressure and is moving closer to my buy area. Finally, I take a look at the charts to find a few opportunities to add to my "house money" position.Analysartikel • Aug 19
Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Jul 07
Affimed: Current Fall And Future Prospects
Affimed did well in the last 12 months, but has been seeing a correction lately. Given a "data rich" 2021, the correction is not correct. Current prices look attractive.Analysartikel • Jun 08
We Discuss Why Affimed N.V.'s (NASDAQ:AFMD) CEO May Deserve A Higher Pay Packet
Shareholders will probably not be disappointed by the robust results at Affimed N.V. ( NASDAQ:AFMD ) recently and they...Analysartikel • Apr 20
Need To Know: Analysts Just Made A Substantial Cut To Their Affimed N.V. (NASDAQ:AFMD) Estimates
Market forces rained on the parade of Affimed N.V. ( NASDAQ:AFMD ) shareholders today, when the analysts downgraded...I detta avsnitt presenterar vi vanligtvis intäkts- och vinsttillväxtprognoser baserade på professionella analytikers konsensusuppskattningar för att hjälpa investerare att förstå företagets förmåga att generera vinst. Men eftersom Affimed inte har tillhandahållit tillräckligt med tidigare data och inte har någon analytikerprognos kan dess framtida resultat inte beräknas på ett tillförlitligt sätt genom att extrapolera tidigare data eller använda analytikerförutsägelser.
Detta är en ganska sällsynt situation eftersom 97% av de företag som omfattas av SimplyWall St har tidigare finansiella uppgifter.
Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 9/30/2024 | 6 | -70 | -77 | -77 | N/A |
| 6/30/2024 | 7 | -79 | -88 | -84 | N/A |
| 3/31/2024 | 9 | -93 | -105 | -101 | N/A |
| 12/31/2023 | 14 | -106 | -114 | -110 | N/A |
| 9/30/2023 | 21 | -119 | -119 | -116 | N/A |
| 6/30/2023 | 34 | -111 | -117 | -117 | N/A |
| 3/31/2023 | 39 | -101 | -110 | -110 | N/A |
| 12/31/2022 | 43 | -86 | -106 | -105 | N/A |
| 9/30/2022 | 42 | -76 | -104 | -102 | N/A |
| 6/30/2022 | 36 | -76 | -111 | -108 | N/A |
| 3/31/2022 | 38 | -76 | -102 | -99 | N/A |
| 12/31/2021 | 42 | -58 | -90 | -87 | N/A |
| 9/30/2021 | 41 | -49 | -45 | -43 | N/A |
| 6/30/2021 | 43 | -38 | -23 | -21 | N/A |
| 3/31/2021 | 36 | -32 | -20 | -19 | N/A |
| 12/31/2020 | 29 | -41 | -20 | -19 | N/A |
| 9/30/2020 | 22 | -39 | -34 | -34 | N/A |
| 6/30/2020 | 14 | -44 | -42 | -42 | N/A |
| 3/31/2020 | 15 | -43 | -34 | -32 | N/A |
| 12/31/2019 | 21 | -32 | -31 | -29 | N/A |
| 9/30/2019 | 41 | -11 | 42 | 44 | N/A |
| 6/30/2019 | 39 | -12 | 44 | 46 | N/A |
| 3/31/2019 | 35 | -9 | 42 | 43 | N/A |
| 12/31/2018 | 24 | -19 | 49 | 49 | N/A |
| 9/30/2018 | 2 | -35 | -30 | -30 | N/A |
| 6/30/2018 | 2 | -31 | N/A | -28 | N/A |
| 3/31/2018 | 2 | -31 | N/A | -25 | N/A |
| 12/31/2017 | 2 | -30 | N/A | -26 | N/A |
| 9/30/2017 | 3 | -29 | N/A | -27 | N/A |
| 6/30/2017 | 3 | -31 | N/A | -28 | N/A |
| 3/31/2017 | 5 | -32 | N/A | -31 | N/A |
| 12/31/2016 | 6 | -32 | N/A | -32 | N/A |
| 9/30/2016 | 7 | -33 | N/A | -30 | N/A |
| 6/30/2016 | 7 | -30 | N/A | -28 | N/A |
| 3/31/2016 | 7 | -27 | N/A | -23 | N/A |
| 12/31/2015 | 8 | -20 | N/A | -19 | N/A |
| 9/30/2015 | 7 | -19 | N/A | -20 | N/A |
| 6/30/2015 | 7 | -5 | N/A | -15 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: Otillräcklig data för att avgöra om AFMD.Q s prognostiserade vinsttillväxt ligger över sparkvoten ( 3.5% ).
Resultat vs marknad: Otillräcklig data för att avgöra om AFMD.Q s intäkter förväntas växa snabbare än marknaden för US
Höga tillväxtresultat: Otillräcklig data för att avgöra om AFMD.Q s intäkter förväntas växa avsevärt under de kommande 3 åren.
Intäkt vs marknad: Otillräcklig data för att avgöra om AFMD.Q s intäkter förväntas växa snabbare än marknaden för US.
Hög tillväxtintäkter: Otillräcklig data för att avgöra om intäkterna från AFMD.Q förväntas växa snabbare än 20% per år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: Otillräcklig data för att avgöra om AFMD.Q s avkastning på eget kapital förväntas bli hög om tre år
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/06 12:37 |
| Aktiekurs vid dagens slut | 2026/05/06 00:00 |
| Intäkter | 2024/09/30 |
| Årlig intjäning | 2023/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Affimed N.V. bevakas av 5 analytiker. 0 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| James Birchenough | BMO Capital Markets Equity Research |
| Brian Abrahams | Jefferies LLC |
| Daina Graybosch | Leerink Partners LLC |